Daebong LS Co., Ltd.
KKRX:0781406,800.00
KRW
-140.00
(-2.02%)
ISIN
KR7078140001
Return %
Stock
S&P 500
1Y
-45.56
13.14
3Y
-19.72
80.78
5Y
-22.55
67.74
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- Full Time Employees
- 138
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Inchon South Korea
- IPO Date
- Dec 23, 2005
- Website
- daebongls.co.kr
- Similar Companies
- Business
- Daebong LS Co., Ltd. is a South Korea-based biotechnology and chemical manufacturing company engaged in the research, development, production, and distribution of active pharmaceutical ingredients, functional cosmetic raw materials, and specialized food additives. Founded in 1986 and headquartered in Incheon, South Korea, the company operates across three primary business segments: Cosmetic Ingredients, Pharmaceuticals, and Food and Feed Additives. Daebong LS serves domestic and international pharmaceutical manufacturers, cosmetics brand owners, nutritional supplement producers, and livestock enterprises across Asia, Europe, and the Americas, maintaining close operational integration with group affiliates including cosmetics contract manufacturer UCL Co., Ltd. and human clinical testing provider P&K Skin Clinical Research Center Co., Ltd. The company offers a comprehensive portfolio of raw materials and formulation solutions, categorized into: Active Pharmaceutical Ingredients (APIs) and pharmaceutical excipients, including respiratory therapeutic agents such as N-acetylcysteine, erdosteine, and S-carboxymethylcysteine; cardiovascular treatments targeting hypertension and hyperlipidemia; gastrointestinal and hepatic therapies; pharmaceutical-grade amino acid derivatives; and custom excipients designed for rapid disintegration, direct compression, and sustained-release delivery; Cosmetic and Personal Care Raw Materials, including precision-fermented bio-actives such as DecelAge peptide; natural botanical extracts derived from Jeju Island; upcycled seed oils and plant-derived lipids; marine bioactive liposomes; fermentation-derived actives such as Gojiberry Kombu; natural thickeners; emulsifiers; skin-brightening and anti-wrinkle agents; and specialized ultraviolet filters; Food and Animal Nutrition Ingredients, including functional dietary supplement raw materials, nutraceutical premixes, amino acid blends, food-grade preservatives, and aquaculture and livestock feed additives; and Advanced Formulation Technologies, encompassing proprietary drug delivery systems (DDS) such as nano-micelles, bio-liposomes, and medical-grade hydrogel matrices designed for active ingredient stabilization and dermal absorption. Recent corporate developments include the completion and operational relocation of its corporate headquarters and primary research center to the Songdo B&H (Beauty and Health) Plex in Incheon's Songdo International Business District, creating an integrated R&D, clinical evaluation, and manufacturing hub alongside its key affiliates. Daebong LS has also advanced its strategic partnerships and research pipeline through a domestic distribution alliance with Lubrizol Life Science for Lipotec cosmetic peptide ingredients; a joint development agreement with LG Chem to commercialize functional cosmetic ingredients based on 100% bio-based 3-hydroxypropionic acid (3HP); a collaborative project with Kolmar BNH to develop next-generation plant-based protein drug delivery platforms; and participation in a government-backed national research consortium alongside GS Caltex focused on precision-fermented lutein production.